Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biopreparedness Act of 2005

This article was originally published in The Gray Sheet

Executive Summary

Product liability provisions in S 3 address perceived shortcomings of Bioshield Act of 2004. The new language, including a noneconomic damages cap of $250,000 - awardable only for physical harm - would benefit manufacturers, distributors and providers of any "equipment, service (including support services), device, or technology (including information technology) designed...for the specific purpose of preventing, detecting, identifying, or preventing a pandemic or epidemic." Introduced Jan. 24 by Sen. Judd Gregg (R-N.H.), the bill was referred to the Finance Committee...
Advertisement

Related Content

BioShield Law Deflects Devices With Commercial Opportunity – Aethlon CEO
Advertisement
UsernamePublicRestriction

Register

MT021548

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel